Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on Arrow Exploration

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on Colombia-focussed oil firm Arrow Exploration from 50.0p to 44.0p on Thursday but acknowledged that near-term drilling was likely to reboot production growth. Canaccord Genuity said Arrow's recent operations update highlighted, in its view, the limitations of normal vertical/near-vertical wells to deliver "significant growth" at the company's Tapir licence in Colombia.

The Canadian bank also stated that Arrow's step-up in production in H224 was driven by horizontal drilling at its CN field, and that it thinks its operational template will likely have the most impact across the licence from now.

"The stock has reacted sharply downwards following the recent update. We recognise the market's disappointment as production has declined over the past couple of months, but the company is only in the very early stages of its 2025 operational programme," said Canaccord.

"We believe the forward drilling plans should set the path upwards once again from early Q2, and with the momentum backed by a strong balance sheet ($23.0m cash and no debt at 1 February) we maintain our 'buy' rating."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.